focus -WSS

focus

author：knowledge 2025-09-30 22:05:34 - browse：974

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Dog Aging Project founders on what lies ahead after losing funding

knowledge

WSS

Future doctors need a strong humanities education

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

The inclusion problem at the heart of rehabilitation research

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Dog Aging Project founders on what lies ahead after losing funding

knowledge

focus

focus

The cancer drug shortage isn’t new — and neither are the solutions

Stroke rates rising, especially in working

Tori Bowie and the unacceptable rates of Black maternal death

U.S. death rates show how politics are affecting public health

Alkermes shareholders re

Cardiologists urge adding sexual orientation, gender identity to health records

Cancer drug shortages should be causing more outrage

Pumping milk in bathrooms at health conferences is common

Medicare details structure of new drug price negotiation program

Update the Apgar Score to remove skin color

focus

Stroke rates rising, especially in working

Medicare bonuses could stop drug shortages under Senate plan

HPV vaccine, cervical cancer study delivers historic results

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Unmasking the 'centricity' illusion in clinical trials

Medicare bonuses could stop drug shortages under Senate plan

knowledge

hotspot

knowledge

focus